Metabolic · For Fat Loss
Cagrilintide for Fat Loss
Amylin analog co-developed with semaglutide as 'CagriSema' for next-gen weight loss.
Why Cagrilintide for fat loss?
Long-acting amylin receptor agonist. CagriSema (cagrilintide + semaglutide) Phase 3 (REDEFINE) reported up to 22% weight loss.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Cagrilintide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Augments GLP-1 weight loss
Reference dosing by bodyweight
Anchored to the most-cited research dose (160 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 100–135 mcg |
| 60–75 kg / 132–165 lb | 122–166 mcg |
| 75–90 kg / 165–198 lb | 150–202 mcg |
| 90–105 kg / 198–231 lb | 177–239 mcg |
| >105 kg / >231 lb | 204–276 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Injection-site reaction
- Injection-site histamine-type reactions / urticaria (reported by community users; clinical incidence not established)
Calculator
Reconstitute Cagrilintide
Reference
Full bodyweight chart
Profile
Cagrilintide guide
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.